2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

2:30PM-4:00PM: Abstract Number: 3001

Lumbar CT-Guided Steroid Infiltration on the Refractory Low Back Pain. Study of 258 Procedures in the Same Center

Orthopedics, Low Back Pain and Rehabilitation

2:30PM-4:00PM: Abstract Number: 3024

Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

2:30PM-4:00PM: Abstract Number: 2993

Membrane-Type 1 Matrix Metalloproteinase Controls Osteo- and Chondrogenesis By a Proteolysis-Independent Mechanism Mediated By Its Cytoplasmic Tail

Biology and Pathology of Bone and Joint

2:30PM-4:00PM: Abstract Number: 2997

Microrna-29a Curtails Synovitis in the Development of Knee Osteoarthritis By Disrupting VEGF

Biology and Pathology of Bone and Joint

2:30PM-4:00PM: Abstract Number: 3048

Pain Severity As a Mediator of the Effect of Depressive Symptoms on Physical Performance in Knee Osteoarthritis

ARHP V: Epidemiology and Public Health

2:30PM-4:00PM: Abstract Number: 3042

PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions

Vasculitis III: Pathogenic Mechanisms

2:30PM-4:00PM: Abstract Number: 3050

Post-Partum Complications and Depression in New Mothers with Juvenile Arthritis

ARHP V: Epidemiology and Public Health

2:30PM-4:00PM: Abstract Number: 3049

Prevalence of Doctor-Diagnosed Arthritis Among Adults with Clinically Measured Pre-Diabetes— United States, 2009–2014

ARHP V: Epidemiology and Public Health

2:30PM-4:00PM: Abstract Number: 3031

Rethinking Primary Sjögren’s Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains?

Sjögren's Syndrome I: Clinical Insights

2:30PM-4:00PM: Abstract Number: 2989

Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort

2016 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3009

Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 3033

Safety and Efficacy of Single Dose VAY736 (anti-BAFF-R mAb) in Patients with Primary Sjögren’s Syndrome (pSS)

Sjögren's Syndrome I: Clinical Insights

2:30PM-4:00PM: Abstract Number: 3000

Safety of the Knee Needle Arthroscopy: A Review of 1136 Procedures in 919 Patients

Orthopedics, Low Back Pain and Rehabilitation

2:30PM-4:00PM: Abstract Number: 3019

Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 3014

Tapering of Adalimumab Based on Therapeutic Drug Monitoring in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].